We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

Back to rankings

220 hedge funds and large institutions have $5.24B invested in Kite Pharma, Inc. in 2017 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 82 increasing their positions, 74 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more call options, than puts

Call options by funds: $167M | Put options by funds: $82.6M

100% more funds holding in top 10

Funds holding in top 10: 5 → 10 (+5)

48% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 27

38% more capital invested

Capital invested by funds: $3.81B → $5.24B (+$1.43B)

11% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 74

5% more funds holding

Funds holding: 209 → 220 (+11)

Holders
220
Holders Change
+11
Holders Change %
+5.26%
% of All Funds
5.48%
Holding in Top 10
10
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+100%
% of All Funds
0.25%
New
40
Increased
82
Reduced
74
Closed
27
Calls
$167M
Puts
$82.6M
Net Calls
+$84.2M
Net Calls Change
+$79.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$156M
2
PHS
PFM Health Sciences
California
+$73.3M
3
ACA
Avoro Capital Advisors
New York
+$65.8M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$39.2M
5
BlackRock
BlackRock
New York
+$30.5M

Top Sellers

Rank Fund Capital Flow
1
BII
Bainco International Investors
Massachusetts
-$69.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$58.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$31.2M
4
HCM
Highline Capital Management
New York
-$30.5M
5
Jennison Associates
Jennison Associates
New York
-$29.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
226
Sculptor Capital
New York
– -$4.07M -51,900 Closed
CM
227
Castleark Management
Illinois
– -$3.38M -43,110 Closed
Two Sigma Investments
228
Two Sigma Investments
New York
– -$3.11M -39,569 Closed
EI
229
EAM Investors
California
– -$2.98M -37,995 Closed
HSA
230
Hussman Strategic Advisors
Maryland
– -$2.75M -35,000 Closed
SFM
231
Sphera Funds Management
Israel
– -$2.75M -35,000 Closed
SSA
232
Schonfeld Strategic Advisors
New York
– -$2.43M -30,966 Closed
OAC
233
OMERS Administration Corp
Ontario, Canada
– -$1.58M -20,200 Closed
PI
234
Putnam Investments
Massachusetts
– -$1.58M -20,161 Closed
Hudson Bay Capital Management
235
Hudson Bay Capital Management
Connecticut
– -$1.53M -19,500 Closed
GA
236
Geneva Advisors
Illinois
– -$1.35M -17,165 Closed
Millennium Management
237
Millennium Management
New York
– -$1.27M -16,140 Closed
CLCM
238
Crawford Lake Capital Management
New Jersey
– -$1.1M -14,000 Closed
JGC
239
J. Goldman & Co
New York
– -$879K -11,200 Closed
FAAS
240
First Allied Advisory Services
California
– -$353K -4,498 Closed
VKH
241
Virtu KCG Holdings
New York
– -$335K -4,263 Closed
Balyasny Asset Management
242
Balyasny Asset Management
Illinois
– -$318K -3,900 Closed
Verition Fund Management
243
Verition Fund Management
Connecticut
– -$240K -3,062 Closed
FMA
244
FNY Managed Accounts
New York
– -$14K -180 Closed
IA
245
IFP Advisors
Florida
– -$14K -175 Closed
FWM
246
Focused Wealth Management
New York
– -$1K -9 Closed
PHK
247
Point72 Hong Kong
Hong Kong
– -$1K -7 Closed
6 7 8 9
10

KITE Hedge Fund Activity: Q2 2017 in Review

220 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q2 2017, worth a combined $5.24B — up 38% from $3.81B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new KITE positions and 27 closed out — a net gain of 13 holders — while 82 added to existing stakes and 74 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $156M. The largest seller was Bainco International Investors, cutting an estimated $69.5M.

  • 220 institutional investors held Kite Pharma, Inc. (KITE) as of Q2 2017, up from 209 in Q1 2017.
  • Funds reported $5.24B of Kite Pharma, Inc. stock for Q2 2017, up 38% quarter-over-quarter.
  • 40 funds opened new Kite Pharma, Inc. positions in Q2 2017 and 27 closed out, a net change of +13 holders.
  • The largest Kite Pharma, Inc. buyer in Q2 2017 was T. Rowe Price Associates, an estimated $156M added.
  • The largest Kite Pharma, Inc. seller in Q2 2017 was Bainco International Investors, an estimated $69.5M sold.

Based on aggregated 13F filings for Q2 2017.